Rohit Kedia1, Alicia Lowes1, Sarah Gillis1, Ronald Markert1, Thomas Koroscil1. 1. From the Department of Internal Medicine, Boonshoft School of Medicine, Wright State University, Dayton, Ohio, and the Department of Internal Medicine, University of Nebraska Medical Center, Omaha.
Abstract
OBJECTIVES: Among patients who have undergone total thyroidectomy, do those with thyroid cancer being kept iatrogenically subclinical hyperthyroid (SCH) differ from euthyroid patients in long-term weight change? METHODS: In a retrospective study, medical records identified 291 patients who had undergone a thyroidectomy for differentiated thyroid cancer or benign thyroid disease. Weight, thyroid-stimulating hormone, and levothyroxine dose were measured presurgery and 1, 2, and 3 years postsurgery. RESULTS: Of 291 patients, 147 were in the SCH group and 144 were in the euthyroid group. At all 3 years both groups gained weight from baseline, but the two groups did not differ in weight change from baseline at any time period: year 1 (SCH mean 0.4% ± 6.2% weight gain vs euthyroid group mean 2.2% ± 6.6% weight gain; P = 0.12), year 2 (SCH mean 1.1% ± 9.1% weight gain vs euthyroid mean 2.9% ± 7.8% weight gain; P = 0.22), and year 3 (SCH mean 2.6% ± 9.2% weight gain vs euthyroid mean 3.1% ± 11.1% weight gain; P = 0.49). CONCLUSIONS: Among total thyroidectomy patients, weight change did not differ between SCH patients and euthyroid patients at years 1 through 3. As such, the use of levothyroxine to induce SCH did not lead to long-term weight change when compared with euthyroid patients.
OBJECTIVES: Among patients who have undergone total thyroidectomy, do those with thyroid cancer being kept iatrogenically subclinical hyperthyroid (SCH) differ from euthyroid patients in long-term weight change? METHODS: In a retrospective study, medical records identified 291 patients who had undergone a thyroidectomy for differentiated thyroid cancer or benign thyroid disease. Weight, thyroid-stimulating hormone, and levothyroxine dose were measured presurgery and 1, 2, and 3 years postsurgery. RESULTS: Of 291 patients, 147 were in the SCH group and 144 were in the euthyroid group. At all 3 years both groups gained weight from baseline, but the two groups did not differ in weight change from baseline at any time period: year 1 (SCH mean 0.4% ± 6.2% weight gain vs euthyroid group mean 2.2% ± 6.6% weight gain; P = 0.12), year 2 (SCH mean 1.1% ± 9.1% weight gain vs euthyroid mean 2.9% ± 7.8% weight gain; P = 0.22), and year 3 (SCH mean 2.6% ± 9.2% weight gain vs euthyroid mean 3.1% ± 11.1% weight gain; P = 0.49). CONCLUSIONS: Among total thyroidectomy patients, weight change did not differ between SCHpatients and euthyroid patients at years 1 through 3. As such, the use of levothyroxine to induce SCH did not lead to long-term weight change when compared with euthyroid patients.
Authors: Young Ju Jin; Jeong Hun Hah; Mi Jung Kwon; Ji Hee Kim; Joo-Hee Kim; Sung-Kyun Kim; Bumjung Park; Hyo Geun Choi Journal: Int J Environ Res Public Health Date: 2022-05-31 Impact factor: 4.614
Authors: Naykky Singh Ospina; Ana Castaneda-Guarderas; Oksana Hamidi; Oscar J Ponce; Wang Zhen; Larry Prokop; Victor M Montori; Juan P Brito Journal: Thyroid Date: 2018-05 Impact factor: 6.568